1. Introduction {#sec1}
===============

Chemotherapy-associated peripheral neuropathy (CAPN) is a neurological side effect of chemotherapy characterized by loss of sensation in the hands and feet, burning or tingling in limbs, and, in some cases, loss of hearing and blurred vision. The neuropathic symptoms are progressive and tend to increase as chemotherapy treatment proceeds. In addition, comorbid conditions may exacerbate the severity of CAPN \[[@B1]\]. For example, diabetes can lead to peripheral neuropathy, and diabetic patients with pre-existing nerve damage may be predisposed to more severe forms of CAPN \[[@B2]--[@B4]\].

The chemotherapy drugs most commonly associated with CAPN are taxanes (paclitaxel and docetaxel), vinca alkaloids (vincristine and vinorelbine), and platinums (cisplatin, carboplatin, and oxaliplatin). The incidence of CAPN varies by drug and dose and can range across products from 4--92% \[[@B1], [@B2], [@B5], [@B6]\]. For example, clinical trials of paclitaxel in breast cancer list incidence rates for severe CAPN between 2--33%, with overall CAPN rates upwards of 60% \[[@B3], [@B7], [@B8]\]. Currently, there are no standard treatments to prevent or mitigate CAPN, although several drug classes (e.g., tricyclic antidepressants, antiepileptic drugs, and adjuvant analgesics) have shown some activity in reducing neuropathic pain \[[@B9], [@B10]\].

Few data exist regarding the health outcomes of CAPN patients, CAPN\'s effects on chemotherapy treatment, and associated costs. However, Berger suggests neuropathies in general can lead to adverse outcomes and higher costs \[[@B11]\]. In particular, Berger found that patients with neuropathies had healthcare costs triple those of controls; however, the study did not examine the costs associated with chemotherapy-related neuropathies specifically \[[@B11]\].

Calhoun conducted a pilot study on the medical and workloss costs associated with chemotherapy-induced toxicities in women with ovarian cancer \[[@B12]\]. Using survey data on 42 patients suffering from chemotherapy-induced neurotoxicities, the study found the medical costs directly attributable to CAPN were \$688 per episode but that indirect costs (patient and caregiver workloss and paid caregiver costs) were over \$4,200 per episode. This pilot study relied on patient recall of medical services used over 3-month intervals. In addition, the sample was limited to women with ovarian cancer and did not consider other cancer types.

To the authors\' knowledge, no study has quantified the comprehensive health outcomes, medical costs, and workloss burden of CAPN patients with breast, ovarian, head/neck, or nonsmall cell lung cancer (NSCLC). The purpose of the current study is to assess health outcomes as well as the healthcare (i.e., medical and drug) and workloss cost burden of CAPN patients (cases) in these 4 tumor types from a third-party payor/employer perspective. The first objective is to compare the healthcare costs of CAPN cases with those of matched controls who have the same cancer but no CAPN. The second objective is to compare workloss costs in patients with and without CAPN. The third objective is to compare the healthcare costs of CAPN cases and non-CAPN controls who have comorbid diabetes. By examining these 4 tumor types, this study captures the use of the chemotherapeutic agents most commonly associated with CAPN.

2. Methods {#sec2}
==========

2.1. Data {#sec2.1}
---------

Data were obtained from a database of privately insured administrative claims records (Ingenix Employer Database) that included approximately 8 million beneficiaries from 40 large US-based companies (1999--2006). The companies have operations nationwide in a broad array of industries and job classifications. The database contains de-identified beneficiary information including demographics (e.g., age and gender), enrollment, and medical and pharmacy claims. Utilization measures include date of service, diagnoses, procedures, and actual payments to providers. Pharmaceutical drug claims include National Drug Code (NDC), fill date, days of supply, quantity, and actual payments. In addition, disability claims and employee wage information were available for employees in 23 companies.

2.2. Sample Selection {#sec2.2}
---------------------

Three analytic samples consisting of CAPN cases and matched non-CAPN controls were used for this study. The main sample, consisting of cases and controls without diabetes, was used to evaluate the healthcare costs and resource use associated with CAPN patients. A sample of cases and controls with diabetes was used in the secondary analysis to evaluate the costs and resource use associated with diabetic CAPN patients. Finally, a subsample of employed cases and controls was used to assess the workloss burden associated with CAPN patients. [Table 1](#tab1){ref-type="table"}(a) presents the sample selection.

### 2.2.1. Main CAPN Sample {#sec2.2.1}

Patients under age 65 were eligible for inclusion in the main sample if they had at least 1 claim with a diagnosis for 1 or more of the following cancers from 1999--2005: NSCLC, breast, ovarian, or head and neck. The cancer types were identified using ICD-9-CM codes (see [Table 1(b)](#tab1){ref-type="table"}). To identify NSCLC from the overall lung cancer sample, patients receiving chemotherapy regimens characteristic of treatment for small cell lung cancer (SCLC) were excluded. SCLC treatment was defined in this study as doublet therapy with a platinum agent in combination with irinotecan, topotecan, or etoposide, or CCNU, melphalan, and VP-16 CAV regimen chemotherapy treatments. Of the patients with a claim for a qualifying tumor, only those with a procedure code indicating chemotherapy administration within 3 months of a claim for a qualifying tumor were selected. The date of first such chemotherapy administration was considered the index date. To ensure that the index event marked the start of a new line of chemotherapy for the tumor, patients were required to have at least 3 months of continuous eligibility prior to the index date with no claims for chemotherapy. Since no specific diagnosis code exists for CAPN, the authors developed an algorithm to define peripheral neuropathy (PN) using ICD-9-CM codes for related diagnoses and symptoms (see [Table 1(b)](#tab1){ref-type="table"}). Any PN defined in the 9 months following the index date was assumed to be CAPN. Thus, patients were classified as CAPN if they had evidence of PN within 9 months of first chemotherapy treatment but had no evidence in the 3-month baseline period. Finally, for this sample, patients with evidence of diabetes (i.e., a diagnosis of 250.x) from at least 3 months up to 12 months prior to the index date or during the 12 months following the index date were excluded.

### 2.2.2. Diabetic CAPN Sample {#sec2.2.2}

A sample of patients with 1 of the 4 tumor types, CAPN, and diabetes were selected for the secondary analysis. The patient selection criteria were the same as in the Main CAPN sample with the exception of the diabetes criteria. Specifically, diabetic CAPN patients were identified as those patients with a diagnosis of ICD-9-CM code 250.x anytime from at least 3 months up to 1 year prior to the index date or during the 12 months following the index date.

### 2.2.3. CAPN Employee Sample {#sec2.2.3}

A subsample of patients from the Main CAPN and Diabetic CAPN samples who were employees with disability data were selected for the workloss cost analysis. Note that this sample will not contain all employed persons from the main and diabetic CAPN samples but rather will only include the employees of the subset of companies with disability data available.

### 2.2.4. Study Period for All Samples {#sec2.2.4}

The study period encompassed the 12 months following the index date. Since the perspective adopted was that of the payor and the payor incurs no cost for patients who withdraw from coverage, no requirements were placed on the length of continuous eligibility following the index event. The baseline period for assessing patient history extended 3 months prior to the index date except for ascertaining the presence of diabetes. In all cases, the patients were required to have a minimum of 3 months eligibility prior to the index date to qualify for the study.

2.3. Matching {#sec2.3}
-------------

Cases in the main CAPN sample and the diabetes CAPN sample were separately matched to controls selected from among the set of NSCLC, breast, ovarian, and head/neck cancer patients receiving chemotherapy who did not have a diagnosis for CAPN-related symptoms at any time in the claims history and were under age 65. Controls were matched to cases based on age, gender, employment status (employee versus nonemployee), cancer type, index date of chemotherapy, length of followup (controls were required to have postindex eligibility of at least as long as their matched case), and the estimated likelihood of developing CAPN. Each case was matched 1 : 1 to a control using an optimal matching algorithm \[[@B13]\]. Likelihood of developing CAPN was derived as a propensity score from a logistic regression model based on resource use and comorbidities during the baseline period. Specifically, the model included age, sex, Charlson Comorbidity Index (CCI) \[[@B14]\], number of inpatient, primary care, oncology, neurology, and other physician visits, and binary variables indicating whether patient went to the emergency room or had depression or uncomplicated hypertension.

The time period over which controls contributed to the outcomes measures was truncated at the end of the observation period for their matching case (i.e., the earlier of either 12 months or when cases dropped from the database).

2.4. Measures {#sec2.4}
-------------

Healthcare costs were stratified into 3 mutually exclusive groups: chemotherapy costs, drug costs, and medical costs. Costs were computed as the paid (reimbursed) amount by the insurer to the health-care provider and were annualized to 2006 U.S. Dollars using the Consumer Price Index for medical care. Chemotherapy costs included medical claims with a chemotherapy procedure code and pharmacy claims for oral chemotherapy agents, identified by NDCs. Drug costs included all pharmaceutical claims other than chemotherapy claims. Medical costs included claims for inpatient, emergency department (ED), and outpatient/other care. Costs included all claims associated with any service provided to the case/control during the study period regardless of diagnosis, procedure, or drug. The subset of pharmaceutical and medical costs that could be directly attributed to CAPN was estimated as follows: CAPN-related drug costs included those for drugs potentially used for CAPN (i.e., amitriptyline, gabapentin, amifostine, glutamine, tricyclic antidepressants, anti-epileptics, NSAIDs, and opioids) and CAPN-related medical costs included those from claims with a primary or secondary diagnosis of a CAPN-related symptom (see [Table 1(b)](#tab1){ref-type="table"}).

Healthcare resource use consisted of hospitalizations, emergency department (ED), and outpatient/other services (reported by type of visit). The resource use components were defined using provider specialty codes and/or place of service codes on the claims. All claims during the study period were included in assessing resource use, regardless of the underlying reason for a visit. In addition, the proportion of patients using CAPN-related drugs, and specific chemotherapy agents were measured.

Workloss days and costs consisted of disability and medically related absenteeism. Workloss costs during the 12-month study period included actual employer payments for disability days plus imputed costs for medically related absenteeism. Medically related absenteeism costs were imputed by multiplying the number of days with medical services resource use by the employee\'s wage: each hospitalization day accounted for a full day of workloss, and outpatient visits accounted for half a day of workloss. As with healthcare costs, total workloss costs were not limited to only those related to a particular condition.

Patient characteristics included demographics, employment status (employee versus nonemployee), cancer type, cancer stage (metastatic versus not metastatic), and comorbidities identified using claims during baseline period and the 12-month study period. Metastatic cancer was defined using claims with diagnoses for metastases (ICD-9-CM codes 196.0-199.1). The CCI was calculated from the claims data and individual physical comorbidities included in the index which were also identified \[[@B14]\].

2.5. Statistical Analyses {#sec2.5}
-------------------------

Baseline characteristics (demographics, comorbidities, resource use rates) were summarized as proportions of the sample with the characteristic. Continuous measures (e.g., healthcare costs, workloss costs, resource use amount) were summarized by mean and standard deviation. Comparisons of matched pairs of categorical variables used McNemar tests. Comparisons of the differences in continuous measures between cases and controls used paired *t*-tests. Excess costs of CAPN cases compared with controls (i.e., costs of CAPN cases minus those of controls) were compared between diabetic and nondiabetic patients using a 2-sample *t*-test. All analyses were conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC). *P*-values less than or equal to 0.05 were considered statistically significant.

3. Results {#sec3}
==========

The main study sample for the healthcare cost and resource use analysis contained 454 cases and controls without diabetes (see [Table 1(a)](#tab1){ref-type="table"}). The diabetes sample for the secondary analysis contained 71 diabetic cases and controls. The employee subsample for the workloss cost and resource use analysis contained 78 cases and controls.

3.1. Baseline Characteristics {#sec3.1}
-----------------------------

Tables [2](#tab2){ref-type="table"}(A) and [3](#tab3){ref-type="table"}(A) show the baseline comparison of CAPN cases and their matched non-CAPN controls within the main sample. Cases and controls were balanced in terms of types of cancer and CCI. However, CAPN cases had more congestive heart failure (4% versus 2%, *P* = 0.0412) and uncomplicated hypertension (17% versus 11%, *P* = 0.0164), whereas the control group had a higher rate of complicated hypertension (3% versus 1%, *P* = 0.0290). Resource use was generally the same between cases and controls; however, there were more cases with neurology specialist visits than controls (5% versus 2%, *P* = 0.0482). The number of neurology visits and neurology costs were not significantly different.

3.2. Study Period Descriptive Characteristics, Healthcare Resource Use, and Costs {#sec3.2}
---------------------------------------------------------------------------------

CAPN cases had significantly higher rates and counts of comorbidities and resource use during the study period compared with matched non-CAPN controls (Tables [4](#tab4){ref-type="table"}(A) and [5](#tab5){ref-type="table"}(A)). Significantly more cases had fibromyalgia, obesity, and uncomplicated hypertension during the study period than their matched controls. Cases also had a higher CCI during the study period (4.7 versus 4.1, *P* \< 0.0001). There were no differences in the classes of chemotherapy agents used by cases and controls. The most common chemotherapeutic agents used by cases and controls were taxanes (33%, 28%) and platinums (20%, 18%). Significantly more cases used a CAPN-related drug than controls (72% versus 56%, *P* \< 0.0001). Cases had substantially higher rates and amounts of use of both inpatient and outpatient visits during the study period. More cases were hospitalized at least once compared with controls (51% versus 37%, *P* \< 0.0001). CAPN cases had significantly higher rates and amounts of use for all outpatient components except for primary care visits and lab/pathology. More cases saw a neurologist than did controls (29% versus 6%, *P* \< 0.0001).

[Table 6(A)](#tab6){ref-type="table"} shows the healthcare cost comparison for cases and controls. For cases, mean annual per capita healthcare costs were \$69,950 versus \$52,606 per control, with an excess annual per patient cost of \$17,344 (*P* \< 0.0001). Mean excess annual per patient healthcare costs for cases versus controls were \$36,660 for head and neck cancer, \$18,790 for nonsmall cell lung cancer, \$16,940 for breast cancer, and \$5,140 for ovarian and all were statistically significant (data not shown). Cases had significantly higher component costs compared with controls. Outpatient costs were the highest component for both cases and controls. However, the excess costs of outpatient and inpatient components were similar with cases having excess annual outpatient costs of \$8,092 per patient (*P* \< 0.0001) and excess annual inpatient costs of \$7,552 per patient (*P* \< 0.0001). Annual oncology-related costs (i.e., chemotherapy and oncologist specialist costs) were \$22,453 for cases compared with \$19,362 for controls, with the majority of costs being chemotherapy costs (\$16,984 and \$16,169 for cases and controls, resp., *P* = 0.5744). CAPN-related drug and medical costs accounted for approximately 2% of total healthcare costs.

3.3. Workloss and Costs {#sec3.3}
-----------------------

There were no statistically significant differences in workloss measures between the subset of 78 employees with CAPN and their matched non-CAPN controls ([Table 7](#tab7){ref-type="table"}). More cases had disability claims than controls (35% versus 26%, resp.). Cases also had almost twice as many disability days as their matched controls (37.4 versus 20.4 days, resp.). While almost all cases and controls had at least 1 medically related absenteeism day (95% and 97%, resp.), cases missed 6 additional days over the 12-month study period compared with controls.

Average annual workloss costs were approximately 25% higher for cases than controls (\$11,298 versus \$9,043, resp.) with a \$2,255 annual per patient difference ([Table 7](#tab7){ref-type="table"}). Cases had both higher disability and higher medically-related absenteeism costs than controls (\$4,970 versus \$3,356 for disability and \$6,329 versus \$5,687 for medically-related absenteeism). However, workloss cost differences were not statistically significant.

3.4. Secondary Analysis of CAPN and Diabetes {#sec3.4}
--------------------------------------------

Tables [2](#tab2){ref-type="table"}(B) and [3](#tab3){ref-type="table"}(B) show the baseline comparison of diabetic cases and their matched diabetic controls. Cases had more metastatic disease (46% versus 28%, *P* = 0.0374), complicated hypertension (6% versus 0%, *P* = 0.0290), and a higher CCI than controls (6.0 versus 4.5, *P* = 0.0043). Resource use was generally well balanced; however, cases did have more primary care visits than controls (2.75 versus 1.75, *P* = 0.0136). There were no statistically significant differences in baseline costs.

Cases had significantly higher rates and counts of resource use during the study period compared with controls (see Tables [4](#tab4){ref-type="table"}(B) and [5](#tab5){ref-type="table"}(B)). More cases than controls used taxanes (42% versus 24%, *P* = 0.0236). More cases were hospitalized compared with controls (68% versus 45%, *P* = 0.0136) though the days per capita were not statistically different (9.1 versus 6.2 for cases and controls, resp., *P* = 0.2195). Six times as many cases had a neurology specialist visit during the study period compared with controls (42% versus 7%, *P* \< 0.0001). Cases also had 18.4 more outpatient visits during the study period on average than the controls (*P* \< 0.0001). CAPN-related drugs were used by 93% of cases compared with 65% of controls (*P* = 0.0003).

For cases, annual per capita healthcare costs were \$76,555 versus \$54,816 per control, with an excess annual per patient cost of \$21,739 (*P* = 0.0273, [Table 6(B)](#tab6){ref-type="table"}). Annual oncology-related costs were \$25,181 for cases compared with \$15,377 for controls, with the majority of these costs being chemotherapy costs (\$20,990 and \$13,033 for cases and controls, resp., *P* = 0.0670). The diabetic case\'s annual per capita excess costs were higher than the control\'s costs (\$21,739 versus \$17,344), however, this difference was not statistically significant.

4. Discussion {#sec4}
=============

This study is the first to use claims data to estimate the excess costs of CAPN patients in breast, nonsmall cell lung, ovarian, and head and neck cancer over a matched sample of cancer patients without CAPN. This study also included a secondary analysis to examine the excess costs of CAPN patients among patients with comorbid diabetes.

The results suggest that CAPN patients are associated with a significant and substantial economic burden among the privately insured U.S. population. Cases with CAPN had on average \$17,344 higher healthcare costs during the 12-month study period compared with controls without CAPN. Compared with controls, more cases were hospitalized, had an emergency department visit, saw an oncologist or neurologist, and had other outpatient visits. In addition, each case with CAPN averaged 12 more outpatient visits and spent more days in the hospital. This suggests that in addition to the excess cost burden to third-party payors, the patients themselves may (depending on their insurance benefits) experience a large burden in terms of out-of-pocket costs (e.g., copayments, coinsurance) and time spent on medical care.

CAPN can lead to increased costs as a result of services specifically aimed at mitigating the PN (e.g., increased physician visits to monitor the PN, costs of PN treatment) and secondary effects, such as switches in chemotherapy regimens or exacerbated cancer. This study separately estimated the costs for CAPN-related services and found they accounted for less than 2% of healthcare costs during the 12-month study period. While a significantly higher proportion of CAPN patients did use the pharmacologic treatments used to manage neuropathic symptoms, these drugs are often generic or lower cost relative to cancer treatments and overall healthcare costs. CAPN-related medical costs were low suggesting that the excess utilization demonstrated by cases was not directly attributed to CAPN. However, the CAPN-related costs as measured here may understate the true burden related specifically to CAPN. First, because there are no specific diagnoses for CAPN, PN-related diagnoses may be underreported on claims. In addition, the secondary effects of CAPN mentioned above are not included in the CAPN-related subset of costs presented here but rather are included in the chemotherapy, drug, and medical costs.

Overall, this study finds that patients with CAPN experience significantly increased costs and resource use. It is important not to conclude that all of the excess costs are caused by CAPN. Since the cases and controls were matched during the baseline period, the results suggest that CAPN is a serious condition that should be carefully monitored in clinical practice. Improvements to the diagnostic tools for CAPN severity and investigation of therapies that treat CAPN without negatively impacting the cancer treatment could benefit both patients and payors.

Calhoun\'s pilot study of chemotherapy-induced toxicity found that the direct CAPN costs for women with ovarian cancer are \$688 for episodes up to 9 months, compared with our findings that CAPN-related costs are on average \$1,320 over a period up to 12 months \[[@B12]\]. Calhoun\'s study relied on patient reported utilization and standard fee data whereas data here are actual reimbursements, which may, in addition to the difference in length of followup, explain the differences in estimates. Calhoun also analyzed indirect costs based on national labor force, employment, and earnings data, including patient workloss, caregiver workloss, and paid caregiver costs. Calhoun found indirect costs were \$4,220, with 67% of that due to caregiver workloss. Patient workloss costs were \$620 per patient per episode compared with our findings of \$642 per patient per year in excess medically related absenteeism costs. Though Calhoun did not include disability costs, this study found CAPN patients had mean excess per patient per year disability costs of \$1,614. While the workloss findings were not statistically significant, this may be due to the small sample size. It is important to note that the workloss cost estimates reported in this study may differ from actual employer costs depending on the employer\'s paid time off policies.

Healthcare costs and resource use were calculated for diabetic CAPN patients as a secondary analysis as literature suggests that diabetes may exacerbate the risk and severity of CAPN. With the prevalence of diabetes increasing, it is important to assess how diabetic CAPN patients may differ from controls and nondiabetic CAPN patients. The results demonstrated that diabetes may, indeed, be associated with increased cost in patients with CAPN, as excess costs of diabetic CAPN patients were 25% higher than for nondiabetic CAPN patients. However, the comparison between diabetic and nondiabetic CAPN patients was not statistically significant, perhaps due to the small sample of diabetic CAPN patients. In addition, although diabetic cases were balanced with their controls in terms of costs and resource use, a higher proportion of cases had metastatic cancer and the CCI of cases was significantly higher than controls. Both these factors could impact the excess cost findings.

This study is limited by the lack of clinical measures, which is common to research that uses claims data. While propensity score matching was used to adjust for many baseline group differences, the possibility exists of other confounding factors not available in this database. Moreover, because CAPN does not have a specific diagnosis code and is not consistently recorded in claims data, there are challenges in identifying the condition. Physicians may not report CAPN unless the impairment is severe enough to affect a patient\'s activities of daily living or warrant alterations to cancer treatment \[[@B1]\]. Thus, this study may include more severe cases of CAPN and may have under identified CAPN patients. The algorithm used for identifying CAPN in this study has not been validated. It is possible that the PN identified was due to other causes. Another study limitation is that due to data availability, cases and controls are matched using only 3 months of baseline data and information on cancer stage beyond metastatic/nonmetastatic is not available. A longer baseline period using a larger database with clinical information on cancer stage may allow for additional controls. The lack of restrictions on the length of continuous eligibility following index date is another possible limitation. This limitation could potentially lead to censoring of costs if a patient\'s plan were to have withdrawn from the database while the patient was continuing to incur costs; however, no such instances occurred in the study and the average length of followup for patients in the study is 11.1 months. Finally, small sample sizes, particularly in the head and neck, ovarian, workloss cost, and diabetic analyses, limited both the types of comparisons as well as the robustness of the statistical inferences. Though this study reports directional differences in workloss outcome measures, no significant differences were found, potentially due to the small sample size.

5. Conclusion {#sec5}
=============

CAPN patients are associated with significantly higher healthcare costs and resource use in patients with breast, ovarian, head/neck, or NSCLC. The excess healthcare cost of CAPN is underestimated when only the cost for medical or pharmacy claims directly for CAPN is considered. Improvements in clinical assessments and treatments for CAPN would be useful for patients and payors.

R. B. Natale of Cedars-Sinai Medical Center, Los Angeles, CA, USA served as a clinical consultant to the study. The authors would like to thank Rebecca Kaufman for her assistance with this study. Previous presentations of this study are as follows: C. T. Pike, H. G. Birnbaum, R. J. Kaufman, C. E. Muehlenbein, G. M. Pohl, R. B. Natale, direct healthcare and workloss burden of chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer; value Health 2009; 12(3):A1-A19. Oral Presentation ND2 at ISPOR 14th Annual International Meeting, 16--20 May 2009, Orlando, Florida, United States. This study was sponsored by Eli Lilly and Company, Indianapolis, IN, USA. C. Muehlenbein and G. M. Pohl are employees of Eli Lilly and Company. C. T. Pike and H. G. Birnbaum are employees of Analysis Group, Inc., Boston, MA, which received funding for this study.

###### 

Inclusion criteria and ICD-9-CM codes used for analytic samples.

###### 

\(a\) Inclusion criteria

      Criteria                                                                                                                                                            Number of patients
  --- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  1   Number of beneficiaries under 65 at eligibility start                                                                                                               4,729,443
  2   \>1 breast, ovarian, head and neck, or nonsmall cell lung cancer claim from 1999--2005                                                                              56,261
  3   \>1 chemotherapy treatment within 3 months following a breast, ovarian, head and neck, or nonsmall cell lung cancer diagnosis                                       14,142
  4   \>3 months of continuous eligibility prior to the first chemotherapy treatment for the qualifying tumor during which no other chemotherapy treatment was received   11,009
  5   \>1 diagnosis for peripheral neuropathy following first chemotherapy treatment                                                                                      1,245
  6   Peripheral neuropathy within 9 months of first chemotherapy treatment                                                                                               525
      Main CAPN sample: no diabetes history                                                                                                                               454
      Diabetic CAPN sample                                                                                                                                                71
      Employee CAPN subsample                                                                                                                                             78

###### 

\(b\) ICD-9-CM Diagnosis Codes Used for Identification of CAPN and Cancer

  CAPN                                     ICD-9-CM code
  ---------------------------------------- ----------------------------------------------------------------------------
  Polyneuropathy due to drugs              357.6
  Disturbance of skin sensation            782.0
  Inflammatory and toxic neuropathy        357.x
  Toxic optic neuropathy                   377.34
  Reflex sympathetic dystrophy             337.2
  Cervical root lesions                    353.2
  Lumbosacral root lesions                 353.4
  Other mononeuritis of unspecified site   355.7
  Mononeuritis of unspecified site         355.9
  Neuralgia, neuritis, or radiculitis      729.2
  Brachial plexus lesions                  353.0
                                           
  Cancer                                   ICD-9-CM code
                                           
  Nonsmall cell lung cancer                162.x
  Breast cancer                            174.x, 175.x
  Ovarian                                  183.x
  Head and neck                            195.0, 140.x, 141.x, 142.x, 143.x, 144.x, 145.x, 146.x, 147.x, 148.x,149.x

###### 

Three-month baseline demographics and comorbidities of CAPN cases and non-CAPN controls.

                                        \(A\) Main Sample: no diabetes   \(B\) Diabetes Sample                                                     
  ------------------------------------- -------------------------------- ----------------------- ------ ----- -------- ------- ------ ------ ----- --------
  Demographics                                                                                                                                     
  Age (mean, SD)                        53.9                             7.5                     53.7   9.3   0.0006   58.5    5.0    57.9   8.3   0.5044
  Gender (*n*, % male)                  69                               15%                     69     15%   1.0000   13      18%    13     18%   1.0000
  Employment Status (*n*, % employed)   75                               17%                     75     17%   1.0000   3       4%     3      4%    1.0000
  Months followup (mean)                11.1                                                     2.2                   11.3           1.7          
   12-month followup                    366                              81%                                           56      79%                 
  Time to CAPN (mean days, SD)          147.5                            82.9                                          137.2   85.7                
   1--3 months                          125                              27%                                           22      31%                 
   3--6 months                          149                              33%                                           26      37%                 
   6--9 months                          179                              39%                                           23      33%                 
                                                                                                                                                   
  Cancer type                                                                                                                                      
  Nonsmall cell lung                    82                               18%                     82     18%   1.000    18      25%    18     25%   1.000
  Breast                                316                              70%                     316    70%   1.000    42      59%    42     59%   1.000
  Ovarian                               28                               6%                      28     6%    1.000    7       10%    7      10%   1.000
  Head and neck                         27                               6%                      27     6%    1.000    4       6%     4      6%    1.000
                                                                                                                                                   
  Metastatic cancer                     168                              37%                     164    36%   0.7883   33      46%    20     28%   0.0374
                                                                                                                                                   
  Comorbidities                                                                                                                                    
  Depressive disorders                  23                               5%                      31     7%    0.2673   2       3%     3      4%    0.6547
  Congestive heart failure              20                               4%                      10     2%    0.0412   7       10%    8      11%   0.7963
  Fibromyalgia                          7                                2%                      7      2%    1.0000   4       6%     1      1%    0.1797
  Obesity                               8                                2%                      2      0%    0.0578   2       3%     0      0%    0.0578
  Hypertension---uncomplicated          76                               17%                     52     11%   0.0164   22      31%    24     34%   0.7316
  Hypertension---complicated            4                                1%                      13     3%    0.0290   4       6%     0      0%    0.0290
  Other cancers                         83                               18%                     74     16%   0.4352   17      24%    21     30%   0.4497
  Charlson Comorbidity Index            4.4                                                      4.3          0.4913   6.0            4.5          0.0043

CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation.

^a^ *P*-values are determined using McNemar tests for proportions and paired t-tests for continuous measures.

###### 

Three-month per-capita baseline resource use and healthcare costs of CAPN cases and non-CAPN controls.

                        \(A\) Main Sample: no diabetes   \(B\) Diabetes Sample                                                                                          
  --------------------- -------------------------------- ----------------------- ---------- ------------ -------------- ---------- ------------ ---------- ------------ --------------
  Resource use rate                                                                                                                                                     
  Hospitalizations      204                              45%                     193        43%          0.4692         43         61%          33         46%          0.1138
  ED visits             75                               17%                     68         15%          0.5139         21         30%          16         23%          0.3980
  Outpatient visits     444                              98%                     445        98%          0.8185         71         100%         70         99%          0.8185
  Oncology              188                              41%                     174        38%          0.3408         26         37%          30         42%          0.4795
  Neurology             22                               5%                      11         2%           0.0482         5          7%           1          1%           0.1025
                                                                                                                                                                        
  Resource use amount   Mean                             (SD)                    Mean       (SD)         *P*-value^a^   Mean       (SD)         Mean       (SD)         *P*-value^a^
                                                                                                                                                                        
  Hospitalizations      1.96                             (5.53)                  1.48       (3.21)       0.0956         3.48       (5.02)       4.10       (9.75)       0.5702
  ED visits             0.24                             (0.70)                  0.21       (0.58)       0.3550         0.41       (0.73)       0.35       (0.76)       0.6310
  Outpatient visits     11.37                            (6.80)                  11.25      (7.40)       0.7449         12.80      (6.08)       11.28      (6.76)       0.1420
  Oncology              1.40                             (3.06)                  1.33       (3.47)       0.6673         1.38       (3.10)       1.44       (2.97)       0.9040
  Neurology             0.06                             (0.31)                  0.03       (0.22)       0.0848         0.07       (0.26)       0.01       (0.12)       0.1029
                                                                                                                                                                        
  Total costs           \$17,797                         (\$22,255)              \$17,180   (\$25,240)   0.6698         \$22,308   (\$24,970)   \$21,061   (\$22,748)   0.6898
   Drug costs           \$433                            (\$857)                 \$467      (\$1,148)    0.6064         \$800      (\$868)      \$646      (\$824)      0.2761
   Medical costs        \$17,363                         (\$22,185)              \$16,712   (\$25,140)   0.6527         \$21,508   (\$24,871)   \$20,415   (\$22,636)   0.7268
    Inpatient           \$6,496                          (\$19,301)              \$5,928    (\$21,811)   0.6632         \$11,220   (\$22,256)   \$9,382    (\$21,412)   0.4845
    ED                  \$127                            (\$826)                 \$102      (\$576)      0.6043         \$125      (\$290)      \$122      (\$340)      0.9490
    Outpatient          \$10,336                         (\$10,186)              \$10,328   (\$10,282)   0.9900         \$9,725    (\$8,672)    \$10,358   (\$9,840)    0.6935
     Oncology           \$438                            (\$1,329)               \$439      (\$1,796)    0.9841         \$379      (\$996)      \$431      (\$1,452)    0.7989
     Neurology          \$10                             (\$61)                  \$9        (\$108)      0.8812         \$24       (\$163)      \$1        (\$7)        0.2435

CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.

^a^ *P*-values are determined using McNemar tests for proportions and paired *t*-tests for continuous measures.

###### 

Chemotherapy agents and comorbidities of CAPN cases and non-CAPN controls during the 12-month study period.

                                               \(A\) Main Sample: no diabetes   \(B\) Diabetes Sample                                                 
  -------------------------------------------- -------------------------------- ----------------------- ----- ----- --------- ----- ----- ----- ----- --------
  Metastatic cancer                            171                              38%                     136   30%   0.0097    30    42%   22    31%   0.1306
                                                                                                                                                      
  Classes of select chemotherapy agents used                                                                                                          
  Taxanes                                      148                              33%                     125   28%   0.0978    30    42%   17    24%   0.0236
  Vinca Alkaloids                              18                               4%                      14    3%    0.4497    3     4%    2     3%    0.6547
  Platinums                                    90                               20%                     80    18%   0.4014    17    24%   20    28%   0.5775
                                                                                                                                                      
  Comorbidities                                                                                                                                       
  Depressive disorders                         68                               15%                     50    11%   0.0804    8     11%   3     4%    0.1317
  Congestive heart failure                     23                               5%                      20    4%    0.6219    12    17%   12    17%   1.0000
  Fibromyalgia                                 37                               8%                      8     2%    \<.0001   8     11%   1     1%    0.0196
  Obesity                                      9                                2%                      2     0%    \<.0001   1     1%    0     0%    0.2568
  Hypertension---uncomplicated                 114                              25%                     83    18%   0.0134    33    46%   35    49%   0.7576
  Hypertension---complicated                   13                               3%                      13    3%    1.0000    5     7%    1     1%    0.1025
  Other cancers^b^                             124                              27%                     101   22%   0.0838    20    28%   19    27%   0.8415
  Charlson Comorbidity Index                   4.7                                                      4.1         \<.0001   7.0         5.6         0.0052

CAPN indicates chemotherapy-associated peripheral neuropathy.

^a^ *P*-values are determined using McNemar tests for proportions and paired *t*-tests for continuous measures.

^b^Other cancers include all cancers other than head and neck, breast, non-small cell lung, and ovarian.

###### 

Resource use of CAPN cases and non-CAPN controls during the 12-month study period.

                                  \(A\) Main Sample: no diabetes   \(B\) Diabetes Sample                                                                     
  ------------------------------- -------------------------------- ----------------------- ------ --------- -------------- ------ --------- ------ --------- --------------
  Resource use rate                                                                                                                                          
  Medical                                                                                                                                                    
   Hospitalizations               231                              51%                     166    37%       \<.0001        48     68%       32     45%       0.0136
   ED visits                      213                              47%                     170    37%       0.0037         42     59%       27     38%       0.0222
   Outpatient visits              453                              100%                    447    98%       0.0339         71     100%      70     99%       0.0339
    Oncology                      288                              63%                     250    55%       0.0075         43     61%       39     55%       0.5050
    Neurology                     133                              29%                     29     6%        \<.0001        30     42%       5      7%        \<.0001
    Primary care                  354                              78%                     345    76%       0.4726         59     83%       60     85%       0.8185
    Other physician               444                              98%                     428    94%       0.0035         71     100%      66     93%       0.0035
    Lab/pathology                 181                              40%                     160    35%       0.1540         21     30%       22     31%       0.8694
    Other outpatient              400                              88%                     369    81%       0.0030         68     96%       61     86%       0.0522
                                                                                                                                                             
  Prescription drug use                                                                                                                                      
   At least 1 CAPN-related drug   329                              72%                     256    56%       \<.0001        66     93%       46     65%       0.0003
                                                                                                                                                             
  Resource use amount             Mean                             (SD)                    Mean   (SD)      *P*-value^a^   Mean   (SD)      Mean   (SD)      *P*-value^a^
                                                                                                                                                             
  Medical                                                                                                                                                    
   Hospitalizations               5.6                              (11.69)                 3.2    (7.77)    0.0001         9.1    (14.38)   6.2    (13.44)   0.2195
   ED visits                      1.1                              (2.80)                  0.6    (1.28)    0.0022         1.6    (1.98)    0.8    (1.35)    0.0064
   Outpatient visits              51.3                             (29.57)                 39.8   (26.81)   \<.0001        56.9   (27.02)   38.5   (25.10)   \<.0001
    Oncology                      12.7                             (18.92)                 9.2    (15.55)   0.0021         12.6   (16.97)   7.5    (10.62)   0.0322
    Neurology                     0.6                              (1.29)                  0.1    (0.51)    \<.0001        1.1    (1.87)    0.1    (0.56)    0.0002
    Primary care                  6.9                              (12.65)                 5.0    (8.74)    0.0085         7.4    (10.25)   5.7    (5.64)    0.2454
    Other physician               22.1                             (21.22)                 17.2   (18.82)   0.0001         25.9   (20.63)   18.6   (18.82)   0.0217
    Lab/pathology                 1.1                              (2.62)                  0.9    (2.49)    0.2127         0.8    (3.59)    1.1    (3.93)    0.6594
    Other outpatient              13.6                             (16.47)                 11.4   (15.97)   0.0349         15.5   (15.37)   11.0   (16.56)   0.0905

CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.

^a^ *P*-values are determined using McNemar tests for proportions and paired *t*-tests for continuous measures.

###### 

Per capita healthcare costs for CAPN cases and non-CAPN controls during the 12-month study period.

                                \(A\) Main Sample: no diabetes   \(B\) Diabetes Sample                                                                                     
  ----------------------------- -------------------------------- ----------------------- ---------- ------------ --------- ---------- ------------ ---------- ------------ --------
  Total healthcare costs        \$69,950                         (\$66,913)              \$52,606   (\$55,554)   \<.0001   \$76,555   (\$63,379)   \$54,816   (\$68,115)   0.0273
                                                                                                                                                                           
  Chemotherapy costs            \$16,984                         (\$21,248)              \$16,169   (\$27,055)   0.5744    \$20,990   (\$31,501)   \$13,033   (\$19,725)   0.0670
                                                                                                                                                                           
  Drug costs                    \$3,744                          (\$5,333)               \$3,071    (\$4,927)    0.0419    \$6,017    (\$7,461)    \$4,223    (\$6,100)    0.1163
   CAPN-related drugs           \$595                            (\$1,590)               \$328      (\$1,041)    0.0016    \$718      (\$1,401)    \$371      (\$782)      0.0832
                                                                                                                                                                           
  Medical costs                 \$49,223                         (\$56,500)              \$33,366   (\$36,931)   \<.0001   \$49,548   (\$46,428)   \$37,561   (\$57,723)   0.1614
   Inpatient                    \$14,050                         (\$35,793)              \$6,498    (\$15,558)   \<.0001   \$19,181   (\$38,190)   \$15,148   (\$44,098)   0.5637
   ED                           \$474                            (\$1,093)               \$263      (\$730)      0.0005    \$798      (\$1,817)    \$243      (\$535)      0.0172
   Outpatient                   \$34,698                         (\$36,712)              \$26,606   (\$29,913)   \<.0001   \$29,569   (\$21,339)   \$22,170   (\$29,244)   0.0921
    Oncology                    \$5,469                          (\$15,923)              \$3,193    (\$8,478)    0.0072    \$4,191    (\$6,950)    \$2,344    (\$4,729)    0.0554
    Neurology                   \$129                            (\$319)                 \$46       (\$433)      0.0011    \$326      (\$843)      \$44       (\$278)      0.0103
    Primary care                \$7,772                          (\$12,454)              \$6,543    (\$9,920)    0.0979    \$6,024    (\$7,341)    \$4,472    (\$5,965)    0.1252
    Other physician             \$7,437                          (\$13,782)              \$6,804    (\$17,452)   0.5247    \$6,235    (\$11,447)   \$5,150    (\$16,025)   0.6502
    Lab/pathology               \$414                            (\$1,825)               \$289      (\$1,490)    0.2632    \$485      (\$2,027)    \$110      (\$193)      0.1237
    Other outpatient            \$13,476                         (\$24,509)              \$9,731    (\$18,345)   0.0064    \$12,307   (\$16,297)   \$10,049   (\$20,812)   0.4798
   CAPN-related medical costs   \$725                            (\$2,005)                                                 \$491      (\$762)                              

CAPN indicates chemotherapy-associated peripheral neuropathy; SD, standard deviation; ED, emergency department.

^a^ *P*-values are determined using McNemar tests for proportions and paired *t*-tests for continuous measures.

###### 

Per capita workloss days and costs during the 12-month study period.

                                     Employee subsample                                       
  ---------------------------------- -------------------- ------------ --------- ------------ --------------
                                                                                              
  Workloss rate^b^                                                                            
   Medically  related  absenteeism   74                   95%          76        97%          0.4142
   Disability                        27                   35%          20        26%          0.2367
                                                                                              
  Workloss days                      mean                 (SD)         Mean      (SD)         *P*-value^a^
                                                                                              
   Medically  related  absenteeism   31.5                 (28.1)       25.3      (18.2)       0.0573
   Disability                        37.4                 (75.4)       20.4      (50.8)       0.1048
                                                                                              
  Workloss costs                     mean                 (SD)         mean      (SD)         *P*-value^a^
                                                                                              
  Total employer costs               \$11,298             (\$11,830)   \$9,043   (\$12,416)   0.2161
   Medically  related  absenteeism   \$6,329              (\$7,136)    \$5,687   (\$6,200)    0.5012
   Disability                        \$4,970              (\$10,994)   \$3,356   (\$10,284)   0.3134

SD indicates standard deviation.

^a^ *P*-values are determined using McNemar tests for proportions and paired *t*-tests for continuous measures.

^b^Workloss rate defined as the number of people with ≥1 disability claim or ≥1 instance of medically-related absenteeism.

[^1]: Academic Editor: Vito Lorusso
